News & Events
< Back to News Overview
CogState Signs Second Agreement with GlaxoSmithKline
13 / 07 / 2007
CogState Ltd (ASX:CGS) announced today that it is has signed a second contract with global research-driven pharmaceutical company, GlaxoSmithKline, for the use of CogState's cognitive testing technology and associated services in a clinical trial due to start this year.
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "CogState's continued revenue growth is dependent upon our ability to work with our pharmaceutical company customers on an on-going basis. We are extremely pleased to be announcing this contract with GlaxoSmithKline, especially on the back of the recent announcement
regarding a second contract with Merck."
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "CogState's continued revenue growth is dependent upon our ability to work with our pharmaceutical company customers on an on-going basis. We are extremely pleased to be announcing this contract with GlaxoSmithKline, especially on the back of the recent announcement
regarding a second contract with Merck."